Therefore, this study aimed to detect the plasma levels of inflammatory cytokine profiles to identify potential biomarkers reflecting the presence of cancer in anti-TIF1-γ antibody-positive DM patients. This evidence concerns the gene TRIM33 and dermatomyositis.